1. Home
  2. DCO vs SNDX Comparison

DCO vs SNDX Comparison

Compare DCO & SNDX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

  • Machine Learning Prediction
  • ML Decision
  • DCO
  • SNDX
  • Stock Information
  • Founded
  • DCO 1849
  • SNDX 2005
  • Country
  • DCO United States
  • SNDX United States
  • Employees
  • DCO N/A
  • SNDX N/A
  • Industry
  • DCO Military/Government/Technical
  • SNDX Biotechnology: Pharmaceutical Preparations
  • Sector
  • DCO Industrials
  • SNDX Health Care
  • Exchange
  • DCO Nasdaq
  • SNDX Nasdaq
  • Market Cap
  • DCO 1.1B
  • SNDX 1.1B
  • IPO Year
  • DCO N/A
  • SNDX 2016
  • Fundamental
  • Price
  • DCO $90.53
  • SNDX $9.63
  • Analyst Decision
  • DCO Strong Buy
  • SNDX Strong Buy
  • Analyst Count
  • DCO 4
  • SNDX 11
  • Target Price
  • DCO $118.50
  • SNDX $34.00
  • AVG Volume (30 Days)
  • DCO 154.9K
  • SNDX 1.8M
  • Earning Date
  • DCO 08-07-2025
  • SNDX 08-04-2025
  • Dividend Yield
  • DCO N/A
  • SNDX N/A
  • EPS Growth
  • DCO 93.69
  • SNDX N/A
  • EPS
  • DCO 2.33
  • SNDX N/A
  • Revenue
  • DCO $789,818,000.00
  • SNDX $43,722,000.00
  • Revenue This Year
  • DCO $5.97
  • SNDX $431.08
  • Revenue Next Year
  • DCO $6.59
  • SNDX $105.38
  • P/E Ratio
  • DCO $38.81
  • SNDX N/A
  • Revenue Growth
  • DCO 3.02
  • SNDX N/A
  • 52 Week Low
  • DCO $51.76
  • SNDX $8.58
  • 52 Week High
  • DCO $91.60
  • SNDX $25.07
  • Technical
  • Relative Strength Index (RSI)
  • DCO 67.79
  • SNDX 48.78
  • Support Level
  • DCO $87.29
  • SNDX $9.03
  • Resistance Level
  • DCO $91.60
  • SNDX $10.54
  • Average True Range (ATR)
  • DCO 2.68
  • SNDX 0.53
  • MACD
  • DCO -0.16
  • SNDX 0.12
  • Stochastic Oscillator
  • DCO 87.45
  • SNDX 50.27

About DCO Ducommun Incorporated

Ducommun Inc provides engineering & manufacturing services for high-performance products & high-cost-of failure applications used primarily in the aerospace and defense, industrial, medical & other industries. The company's reportable segments are Structural Systems & Electronic Systems. Structural Systems designs, engineers and manufactures various sizes of complex contoured aerostructure components and assemblies and supplies composite and metal bonded structures and assemblies. Electronic Systems designs, engineers and manufactures high-reliability electronic and electromechanical products used in worldwide technology-driven markets including A&D and Industrial end-use markets. It generates maximum of its revenue from the Electronic Systems.

About SNDX Syndax Pharmaceuticals Inc.

Syndax Pharmaceuticals Inc is a clinical-stage biopharmaceutical company focused on developing a pipeline of combination therapies in multiple cancer indications. Its product candidates include revumenib and axatilimab. It is developing revumenib, a selective menin-MLL inhibitor for KMT2A-rearranged (MLL-r) and NPM1-mutant acute leukemias, including ALL and AML. It is also developing axatilimab, a CSF-1R-blocking antibody for cGVHD and idiopathic pulmonary fibrosis. Entinostat is its oral, small molecule product candidate that has direct effects on both cancer cells and immune regulatory cells. The business activity of the group is functioned through the region of the United States.

Share on Social Networks: